Cell therapy

T cell receptor
#Adaptimmune Therapeutics #Cell therapy #Collaboration #Galapagos #License agreement #Solid tumours

Companies partner on TCR T-cell therapy for head & neck cancer

Adaptimmune Therapeutics and Galapagos have entered into a clinical collaboration agreement to develop Adaptimmune’s TCR T-cell therapy for head and neck cancer and other potential solid tumours. Under the terms of the agreement, Adaptimmune will receive an upfront exclusivity payment of $70 million, plus $15 million… Read More

#Cancer Research #News

The European Medicines Agency in Amsterdam
#CAR-T #Cell therapy #European Commission #European Medicines Agency #Kite Pharma

EU relaxes safety monitoring of CAR-T therapies

The European Medicines Agency has approved a Type II variation to the Summary of Product Characteristics (SmPC) for Kite’s chimeric antigen receptor (CAR)-T cell therapies, Yescarta (axicabtagene ciloleucel) and Tecartus (brexucabtagene autoleucel). The variation includes a reduction in daily hospital safety monitoring for patients following CAR-T cell therapy infusion from… Read More

#News #Regulatory

Woman using an asthma inhaler
#Asthma #CAR-T #Cell therapy #China #Preclinical investigations

Researchers push asthma into remission with one dose of CAR-T

A single dose of long-lived chimeric antigen receptor (CAR)-T therapy led to sustained repression of lung inflammation and alleviation of asthmatic symptoms in a new study. The paper, ‘A single infusion of engineered long-lived and multifunctional T cells confers durable remission of asthma in mice’, was… Read More

#Editor's Choice #News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

New DDW Highlights podcast: 21 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  From a weight loss drug that prevents heart attacks and a gene therapy that… Read More

#News

#Cardiovascular disease #Cell and gene therapy #Cell therapy #circular RNAs #Gene therapy

This week in drug discovery (13-16 May) 

News round-up for 13-16 May by DDW Senior Digital Content Editor Diana Spencer. From a weight loss drug that prevents heart attacks and a gene therapy that restores hearing, to a vaccine that can treat viruses that don’t exist yet, our chosen news stories this week all represent… Read More

#News

Click chemistry
#Acepodia #Bioorthogonal chemistry #CAR-T #Cell therapy #Click chemistry #Oncology #Phase I trial

First use of click chemistry in CAR-T cell therapy shows promise

Acepodia has announced promising preliminary data from its Phase I dose escalation clinical trial of ACE1831, an anti-CD20 antibody conjugated allogeneic gamma delta T cell therapy being evaluated in patients with non-Hodgkin’s lymphoma (NHL). One out of five patients demonstrated complete response (CR) and three out… Read More

#Cancer Research #News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

New DDW Highlights episode: 8 May 2024

The latest episode of the DDW Highlights podcast is now available to listen to below. DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates.  The ongoing innovation and development in the drug discovery sector relies on a number… Read More

#News

#Allogene Therapeutics #allogeneic cell therapies #Biologics #Biotech #Cancer Research Horizons #Cancer vaccine #CAR-T #Cell therapy #Clinical trials #Drug discovery #Financing #Funding #LifeArc #Oncology #Rare disease #Research and development #Seed funding #Start-ups #University of Dundee #University of Oxford

This week in drug discovery (29 April – 3 May) 

News round-up for 29 April – 3 May by DDW Multimedia Editor Megan Thomas. The ongoing innovation and development in the drug discovery sector relies on a number of moving parts, one of which is financial support and backing. Whether it is successful seed funding or dedicated investment,… Read More

#News

CAR-T therapy
#Allogene Therapeutics #allogeneic cell therapies #CAR-T #Cell therapy #Funding #Oncology

$15 million CIRM grant supports allogeneic CAR-T in renal cell carcinoma

Allogene Therapeutics has received a $15 million grant from the California Institute for Regenerative Medicine (CIRM) to support the development of ALLO-316, an AlloCAR T investigational product for the treatment of advanced or metastatic renal cell carcinoma (RCC). ALLO-316 targets CD70, which is highly expressed in RCC and is also… Read More

#Business & Investment #News

#Bioprinting #Cancer research #Cancer Research Horizons #Cancer Research UK #Cell therapy #Data #Data management #Data security #Drug development #Drug discovery #Electronic Lab Notebooks (ELN) #Laboratory data #Oncology #Organ manufacturing #Start-ups #Tissue engineering

Podcast looks behind the scenes of the drug discovery industry

This is the latest episode of the free DDW narrated podcast, titled “A look behind the scenes of the drug discovery industry” which covers three written for Volume 23 – Issue 4, Fall 2022 of DDW. They are called: Going paperless – the move to electronic lab… Read More

#News

#Cell and gene therapy #Cell therapy #Collaboration #Manufacturing #Partnership

Partnership to speed up cell therapy delivery

Autolomous and BioCentriq have collaborated to digitise and accelerate process development and manufacturing activities for cell therapy. Autolomous’ software platform is designed to materially affect the cell and gene therapy sector. BioCentriq will leverage the autoloMATE platform to streamline its process development operations and enhance client experience. This partnership aims… Read More

#Business & Investment #News

Stem cells
#allogeneic cell therapies #Cell therapy #FDA #Graft vs Host Disease #Phase I trial

FDA green light for trial of allogeneic regulatory T cell therapy

The US Food and Drug Administration (FDA) has accepted an Investigational New Drug (IND) application for Tr1X’s TRX103 for the prevention of Graft versus Host Disease (GvHD) in patients undergoing HLA-mismatched haematopoietic stem cell transplantation (HSCT). The company plans to initiate a Phase I study of the investigational allogeneic off-the-shelf… Read More

#News #Regulatory

Cancer cells
#Breast cancer #Cancer research #CAR-T #Cell therapy #Oncology

eBook: Breakthroughs in oncology research and drug discovery

While the age-adjusted overall cancer death rate in the US fell by 33% between 1991 and 2020, cancer remains a significant threat to human health, with more than two million new cases expected to be diagnosed in 2024 and uneven progress across different cancer types1. These… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #Gene therapy

This week in drug discovery (18-22 March) 

News round-up for 18-22 March by DDW Digital Content Editor Diana Spencer. This has been an interesting week for cell and gene therapies, with two landmark FDA approvals, two significant fundraising efforts and potentially ground-breaking study results in glioblastoma. The top stories: ‘Dual-target’… Read More

#News

#CAR-T #Cell and gene therapy #Cell therapy #Financing #In vivo #Investment

$175M financing will support development of in vivo CAR-T therapies

Biotechnology company Capstan Therapeutics has raised $175 million in an oversubscribed Series B financing. The proceeds will be used to advance CPTX2309, Capstan’s lead in vivo chimeric antigen receptor T cell (CAR-T) candidate, to early clinical proof-of-concept in autoimmune disorders, and to further develop Capstan’s tLNP pipeline. CPTX2309 delivers an… Read More

#Business & Investment #News

CAR-T therapy
#Blood cancer #Bristol Myers Squibb #CAR-T #Cell therapy #FDA #Leukaemia #Oncology

FDA approves first CAR-T cell therapy for relapsed CLL or SLL

The US Food and Drug Administration (FDA) has granted accelerated approval of Breyanzi (lisocabtagene maraleucel; liso-cel), a CD19-directed chimeric antigen receptor (CAR) T cell therapy, for relapsed or refractory chronic lymphocytic leukaemia (CLL) or small lymphocytic lymphoma (SLL). It is approved in adult patients who have received at least two… Read More

#News #Regulatory #Trending News